Aldicarb Quickview (CASRN 116-06-3)

Status of Data for Aldicarb

File First On-Line: 01/31/1987; Last Significant Revision: 11/01/1993

Category (section)	Status	Last Revised
Oral RfD Assessment	On-line	11/01/1993
Inhalation RfC Assessment	No data
Carcinogenicity Assessment	On-line	03/01/1991

Synonyms

116-06-3 Aldecarb Aldicarb Ambush Carbamyl

Carbanolate ENT 27,093 2-Methyl-2-(methylthio)propanal, o-((methylamino)carbonyl) oxime 2-Methyl-2-(methylthio)propionaldehyde o-(methylcarbamoyl)oxime more...

Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect	Point of Departure*	UF	MF	RfD
Sweating as clinical sign of AChe inhibition (other effect: Nausea, diarrhea, and other signs and symptoms. Clinical signs and symptoms of acetylcholinesterase inhibition including sweating, pinpoint pupils, leg weakness, and other effects. )	NOAEL : 0.01 mg/kg-day	10	1	1 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

• Principal and Supporting Studies (Oral RfD)
  • Acute human oral exposure study, Rhone-Poulenc, 1992
• Confidence in the Oral RfD
  • Study -- Medium
  • Database -- Medium
  • RfD -- Medium

Top of page

---

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure

• Weight-of-Evidence Characterization
  • D (Not classifiable as to human carcinogenicity)
• Weight-of-Evidence Narrative:
  • Aldicarb was not found to induce statistically significant increases in tumor incidence in mice or rats in feeding studies or mice in a skin painting study. In the feeding studies there were, however, significant trends in pituitary tumors in female rats and fibrosarcomas in the male mouse. This evidence, together with the fact that less than maximum tolerated doses were used, indicates that the available assays are inadequate to assess the carcinogenic potential of aldicarb.
  • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

---

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

• Not Assessed under the IRIS Program.

---

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

• Not Assessed under the IRIS Program.